What happened with IRWD today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Ironwood Pharmaceuticals’ commercial medicine, LINZESS (linaclotide), treats constipation associated with irritable bowel syndrome, chronic constipation with no known cause, and functional constipation in approved pediatric populations. Ironwood and AbbVie sell it together in the United States. AbbVie records sales, the partners deduct their commercial costs, and they share the resulting profits or losses equally. They also share U.S. development costs. Outside the United States, Ironwood receives sales-based royalties through its linaclotide partnerships, including for sales under the CONSTELLA brand in some markets.
Nearly all revenue comes from linaclotide partnerships, with most coming from U.S. LINZESS sales. This makes Ironwood heavily dependent on AbbVie and on patients filling prescriptions. Insurance coverage, reimbursement and drug pricing affect the money those prescriptions generate; wholesaler and pharmacy purchasing and inventory levels also affect collaboration revenue. Partners handle manufacturing and distribution in their territories.
Ironwood is also developing apraglutide for people with short bowel syndrome who depend on intravenous nutritional or fluid support. It needs a confirmatory late-stage clinical trial to support an application for regulatory approval. Apraglutide is not approved, so Ironwood cannot yet sell it or earn revenue from it.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Ironwood depends primarily on U.S. LINZESS sales economics, while Zealand Pharma’s investigational glepaglutide could compete with its apraglutide opportunity.
Ironwood’s revenue depends heavily on its partnership with AbbVie: they jointly sell the prescription gastrointestinal medicine LINZESS in the United States and split development costs and net profits or losses equally. Watch AbbVie’s U.S. LINZESS net sales and both companies’ commercial costs, which are deducted before the remaining amount is shared.
Ardelyx competes directly with Ironwood for adults with constipation-predominant irritable bowel syndrome, selling IBSRELA against LINZESS. Watch IBSRELA’s sales to this patient group rather than Ardelyx’s separate XPHOZAH business for adults with kidney disease on dialysis.
Takeda already sells treatments in the short bowel syndrome market that Ironwood seeks to enter with apraglutide, which would compete with them if developed and approved. Watch Takeda’s GATTEX in the United States and REVESTIVE in Europe for evidence of demand in that market.
Ardelyx, Inc. earningsARDX
Ardelyx’s report will show how IBSRELA is selling to adults with IBS-C, the patient group where it competes directly with Ironwood’s LINZESS.
Focus on IBSRELA sales, not Ardelyx’s XPHOZAH business for people on dialysis. Strong IBSRELA sales would show the rival gaining traction with this shared patient group and could mean more pressure on LINZESS; weak sales would point to less pressure from this product, not prove LINZESS demand is strong.
Ironwood Pharmaceuticals, Inc. earningsThis company
Ironwood Pharmaceuticals shares U.S. LINZESS profits or losses with AbbVie after commercial costs, and this report will show how prescriptions, net pricing and channel inventory shape Ironwood’s main revenue stream.
Read U.S. LINZESS-related revenue alongside prescription demand. Stable or rising revenue with more prescriptions would show demand growth offsetting lower pricing and channel swings; falling revenue despite more prescriptions would point to net price or inventory outweighing demand, leaving Ironwood exposed to its reliance on this collaboration.
